A mathematical model for maximizing the value of phase 3 drug development portfolios incorporating budget constraints and risk
Crossref DOI link: https://doi.org/10.1002/sim.5731
Published Online: 2013-01-09
Published Print: 2013-05-10
Update policy: https://doi.org/10.1002/crossmark_policy
Patel, Nitin R.
Ankolekar, Suresh
Antonijevic, Zoran
Rajicic, Natasa
Version of Record valid from 2013-01-09
Text and Data Mining valid from 2013-01-09